Table 2. Transition probabilities and hazard coefficients for deaths on antiretroviral therapy.

Variables		Transition probabilities and hazard coefficients (95% CI) per 1 month cycle
		Public-care	Private-care
First 6 months after starting antiretroviral therapy
Transition probability
3 months CD4 0–49 cells/µL		0,035 (0,029 to 0,044)	0,040 (0,029 to 0,056)
3 months CD4 50–199 cells/µL		0,010 (0,008 to 0,012)	0,017 (0,013 to 0,022)
6 months CD4 0–49 cells/µL		0,011 (0,010 to 0,014)	0,027 (0,021 to 0,036)
6 months CD4 50–199 cells/µL		0,003 (0,003 to 0,004)	0,011 (0,009 to 0,014)
First 6 months after restarting antiretroviral therapy
Transition probability: 0–6 months		0,008 (0,004 to 0,016)	0,004 (0,001 to 0,010)
>6 months on antiretroviral therapy
Hazard coefficient due to CD4 and VL
CD4 0–49 cells/µL	VL <1,000 copies/ml	−5,01	−5,03
CD4 0–49 cells/µL	VL 1,000–100,000 copies/ml	−4,71	−4,69
CD4 0–49 cells/µL	VL >100,000 copies/ml	−3,83	−4,13
CD4 50–199 cells/µL	VL <1,000 copies/ml	−6,00	−6,5
CD4 50–199 cells/µL	VL 1,000–100,000 copies/ml	−5,69	−6,16
CD4 50–199 cells/µL	VL <1000 copies/ml	−4,82	−5,6
CD4 200–349 cells/µL	VL >100,000 copies/ml	−7,25	−7,48
CD4 200–349 cells/µL	VL 1,000–100,000 copies/ml	−6,94	−7,14
CD4 200–349 cells/µL	VL <1000 copies/ml	−6,07	−6,58
CD4 350–499 cells/µL	VL >100,000 copies/ml	−7,63	−8,53
CD4 350–499 cells/µL	VL 1,000–100,000 copies/ml	−7,32	−8,19
CD4 350–499 cells/µL	VL >100,000 copies/ml	−6,45	−7,63
CD4 ≥500 cells/µL	VL <1,000 copies/ml	−7,76	−8,16
CD4 ≥500 cells/µL	VL 1,000–100,000 copies/ml	−7,46	−7,82
CD4 ≥500 cells/µL	VL >100,000 copies/ml	−6,58	−7,26
Hazard coefficients for Gompertz function
alpha		0,93 (0,52 to 1,34)	1,73 (1,17 to 2,28)
beta – half-life (months)		20	20